HomeHome
TradeTrade
SpotFuturesStocks
LendLendBPBP
ToolsTools
WatchlistsScreenerGraphsCalendarRates
SupportSupport

More

​$​0123456789​.01234567890123456789​

Today

$0.00

+0.00%

Mkt Cap

Volume

Next Earnings

ChartFinancialsEarningsAbout
Climb Bio, Inc. Common Stock

Climb Bio, Inc. Common Stock

Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.

climbbio.com

Ticker

CLYM

Market cap

$615.83M

IPO Date

Aug 10, 2021

Employees

29

All
Crypto
Stocks
Asset

Brokerage services in your region are provided through Trek Brokerage Services Limited, a company licensed by the Anjouan Offshore Finance Authority, acting as Intermediary Broker pursuant to the Backpack Securities Brokerage Services Terms of Service. Please see our Brokerage Services Terms and Conditions available here. Investing in stocks involves risks, including the total loss of your investment. The value of investments can go down as well as up, and past performance is not a reliable indicator of future results. You should consider seeking independent financial or legal advice before making any investment decision. It is your responsibility to ensure that your use of this platform and any investments made comply with the laws and regulations of your jurisdiction.